LEXINGTON, Mass.--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended March 31, 2009. The company incurred a net loss attributable to common stockholders of $9.7 million, or $0.14 per share, basic and diluted, for the first quarter of 2009, compared with a net loss attributable to common stockholders in the first quarter of 2008 of $11.6 million, or $0.21 per share, basic and diluted. The company’s net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the three months ended March 31, 2009 and 2008 was $9.8 million and $9.4 million, respectively. The 2009 results reflect, among other things, the company’s continued focus on supporting Oncophage in Europe and Russia. Cash, cash equivalents and short-term investments amounted to $24.6 million as of March 31, 2009.
